Medexus Pharmaceuticals Inc. (TSE:MDP) Given Average Rating of “Strong Buy” by Analysts

Medexus Pharmaceuticals Inc. (TSE:MDP) has earned a consensus rating of “Strong Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is C$5.25.

A number of research analysts have issued reports on the stock. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Finally, Raymond James upgraded Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from C$3.00 to C$4.00 in a research note on Wednesday, November 20th.

Medexus Pharmaceuticals Stock Performance

Shares of Medexus Pharmaceuticals stock opened at C$3.45 on Friday. The firm has a 50-day moving average of C$2.66 and a 200-day moving average of C$2.46. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$3.48. The stock has a market cap of C$84.63 million, a PE ratio of 69.00 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.